- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01080898
Evaluation of Optical Coherence Tomography. (ESSO)
July 20, 2012 updated by: Assistance Publique - Hôpitaux de Paris
Evaluation of the Sensitivity and Specificity of Optical Coherence Tomography Combined With Fundus Color Photos for Diagnosis of Choroidal Neovessels in Age-related Macular Degeneration
Determination of the sensitivity and specificity of different combinations of imaging techniques (spectral domain optical coherence tomography, fundus photography and fluorescein angiography) used for the diagnosis of choroidal neovessels complicating age -related macular degeneration.
This information will help to determine the choice of the most suitable combination for the above diagnosis.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The following combinations will be studied: spectral domain optical coherence tomography (OCT) + fundus photography; fluorescein angiography + fundus photography and the combination of all three techniques (OCT+ fundus photography + fluorescein angiography).The sensitivity and specificity of the latter combination will be assessed by comparison with the results for this combination reported by several readers.
Inter- and intra-observer reproducibility of the different combinations will also be studied.
Study Type
Observational
Enrollment (Actual)
151
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients > 50 years with suspicion of choroidal neo-vessels complicating age relatid macular degeneration (DMLA)
Description
Inclusion Criteria:
- Age> 50 years
- First visit for suspicion of choroidal neo-vessels complicating age related macular degeneration
- Fundus color photographs , FLUORESCEIN angiography and OCT prescription
Exclusion Criteria:
- Age < 50 years
- Diabetes
- Central vein occlusion Macular hole Epi-retinal membrane Retinal detachment Macular hemorrhage more than the 1/3 of the lesion
- History of macular laser, PDT or intra-vitreal injection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
DMLA patients
patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
|
color photographs, FLUORESCEIN angiography and OCT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the sensitivity and specificity of optical coherence tomography combined with fundus color photos in the diagnosis of choroidal neovessels in age- related macular degeneration.
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the sensitivity and specificity of fluorescein angiography combined with fundus color photography in the diagnosis of choroidal neovessels in age - related macular degeneration.
Time Frame: all the outcome the day of inclusion
|
all the outcome the day of inclusion
|
Evaluation of the sensitivity and specificity of optical coherence tomography combined with fundus color photography, and of fluorescein angiography combined with fundus color photography.
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Rate of unusable images for each technique
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Evaluation of the sensitivity and specificity of optical coherence tomography combined with fundus color photography for the diagnosis of sub-categories of choroidal neovessels
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Evaluation of the sensitivity and specificity of fluorescein angiography combined with fundus color photography for the diagnosis of sub-categories of choroidal neovessels.
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Evaluation of the intra-and inter-reader reproducibility of the diagnosis of choroidal neovessels in age-related macular degeneration using fluorescein angiography combined with fundus color photography.
Time Frame: all outcome the day of inclusion
|
all outcome the day of inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ramin TADAYONI, MD,PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
January 28, 2010
First Submitted That Met QC Criteria
March 3, 2010
First Posted (Estimate)
March 4, 2010
Study Record Updates
Last Update Posted (Estimate)
July 23, 2012
Last Update Submitted That Met QC Criteria
July 20, 2012
Last Verified
April 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- K080904
- IDRCB 2009-A00670-57 (Other Identifier: AFSSAPS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
Clinical Trials on tests
-
Hospices Civils de LyonCompleted
-
University Hospital, GrenobleUnknownAttention Deficit-HyperactivityFrance
-
University of SussexUniversity of OxfordRecruiting
-
Centre Hospitalier Universitaire de NiceTerminatedAged | Chronic Renal Insufficiency | Chronic Kidney FailureFrance
-
University College, LondonTerminatedDementia | Hearing Loss | Auditory Processing DisorderUnited Kingdom
-
University Hospital, AngersCompletedPresymptomatic Huntington DiseaseFrance
-
University Hospital, AngersAssistance Publique - Hôpitaux de Paris; National Cancer Institute, FranceUnknownHealthy Volunteers | Medulloblastoma, Childhood | Low-grade Glioma | Fossa Posterior TumorFrance
-
University of PecsUnknownPerioperative/Postoperative Complications | Abdominal Aortic Aneurism | Abdominal Aortic Rupture | Surgical Blood Loss
-
CHU de Quebec-Universite LavalCompletedDiabetes Mellitus, Type 1 | Bone Health | Bone FractureCanada
-
Kantonsspital AarauRecruiting